Table 4:
Risk of hospital admission secondary to gallbladder disease associated with six months of continuous use of oral contraceptives, by type of progestin
| Progestin | Crude rate ratio (95% CI) | Adjusted rate ratio* (95% CI) |
|---|---|---|
| Levonorgestrel | 1.00 (ref) | 1.00 (ref) |
| Desogestrel | 0.95 (0.94–0.97) | 0.99 (0.98–1.00) |
| Drospirenone | 1.45 (1.43–1.46) | 1.10 (1.09–1.12) |
| Ethynodiol diacetate | 0.95 (0.93–0.97) | 1.04 (1.01–1.06) |
| Norethindrone | 1.07 (1.06–1.08) | 1.09 (1.08–1.10) |
| Norgestimate | 1.00 (0.99–1.01) | 0.99 (0.98–1.00) |
| Norgestrel | 1.08 (1.06–1.10) | 1.06 (1.05–1.08) |
Note: CI = confidence interval, ref = reference group.
*
Adjusted for age, calendar time, sickle-cell anemia, diabetes mellitus, inflammatory bowel disease, obesity, pancreatitis, smoking, and use of statins and fibrates.